AMENDMENTS TO THE CLAIMS

The following list of claims will replace all prior claims in the application:

1. (Currently amended) ~~Compounds of the general~~ A compound of formula **I**



Formula **I**

wherein

X represents -O-; -S-; -SO-; or -SO_2-;

W is a six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in *meta* or *para* position;

V represents a bond; -$(CH_2)_r$-; -A-$(CH_2)_s$-; -CH_2-A-$(CH_2)_t$-; -$(CH_2)_s$-A-; -$(CH_2)_2$-A-$(CH_2)_u$-; -A-$(CH_2)_v$-B-; -CH_2-CH_2-CH_2-A-CH_2-; -A-CH_2-CH_2-B-CH_2-; -CH_2-A-CH_2-CH_2-B-; -CH_2-CH_2-CH_2-A-CH_2-CH_2-; -CH_2-CH_2-CH_2-CH_2-A-CH_2-; -A-CH_2-CH_2-B-CH_2-CH_2-; -CH_2-A-CH_2-CH_2-B-CH_2-; -CH_2-A-CH_2-CH_2-CH_2-B-; -CH_2-CH_2-A-CH_2-CH_2-B-; -O-CH_2-$CH(OCH_3)$-CH_2-O-; -O-CH_2-$CH(CH_3)$-CH_2-O-; -O-CH_2-$CH(CF_3)$-CH_2-O-; -O-CH_2-$C(CH_3)_2$-CH_2-O-; -O-CH_2-$C(CH_3)_2$-O-; -O-$C(CH_3)_2$-CH_2-O-; -O-CH_2-$CH(CH_3)$-O-; -O-$CH(CH_3)$-CH_2-O-; -O-CH_2-$C(CH_2CH_2)$-O-; or -O-$C(CH_2CH_2)$-CH_2-O-;

A and B independently represent -O-; -S-; -SO-; or -SO_2-;

U represents aryl; or heteroaryl;

T represents -$CONR^1$-; -$(CH_2)_pOCO$-; -$(CH_2)_pN(R^1)CO$-; -$(CH_2)_pN(R^1)SO_2$-; or -COO-;

Q represents lower alkylene; or lower alkenylene;

M represents hydrogen; cycloalkyl; aryl; heterocyclyl; or heteroaryl;

R^1 represents hydrogen; lower alkyl; lower alkenyl; lower alkinyl; cycloalkyl; aryl; or cycloalkyl-lower alkyl;

p is the integer 1, 2, 3 or 4;

r is the integer 3, 4, 5, or 6;

s is the integer 2, 3, 4, or 5;

t is the integer 1, 2, 3, or 4;

u is the integer 1, 2, or 3; and

v is the integer 2, 3, or 4;

[[and]] or optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, [[and]] or the meso-form of the compound; ~~as well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

2. (Currently amended) ~~Compounds of general~~ The compound of formula I according to claim 1, wherein ~~X, W, V, and U are as defined in general formula I and~~

T represents -$CONR^1$-;

Q represents methylene; and

M represents aryl, or heteroaryl;

[[and]] or optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, [[and]] or the meso-form of the compound; ~~as well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

3. (Currently amended) ~~Compounds of general~~ The compound of formula **I** according to claim 1, wherein ~~X, W, U, T, Q, and M are as defined in general formula I and~~

V represents $-CH_2CH_2O-$; $-CH_2CH_2CH_2O-$; or $-OCH_2CH_2O-$;

[[and]] or optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, [[and]] or the meso-form of the compound; ~~as well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

4. (Currently amended) ~~Compounds of general~~ The compound of formula **I** according to claim 1, wherein ~~X, V, U, T, Q, and M are as defined in general formula I and~~

W represents a 1,4-disubstituted phenyl group;

[[and]] or optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, [[and]] or the meso-form of the compound; ~~as well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

5. (Currently amended) ~~Compounds of general~~ The compound of formula I according to claim 1, wherein ~~X, W, V, Q, T, and M are as defined in general formula I and~~

U is a mono-, di-, or trisubstituted phenyl or heteroaryl, whereby the substituents are selected from the group consisting of halogen, lower alkyl, lower alkoxy, and CF_3

[[and]] or optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, [[and]] or the meso-form of the compound; ~~as well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

6. (Currently amended) The ~~compounds~~ compound according to ~~any one of claims 1 to 5~~ claim 1 selected from the group consisting of:

(*rac.*)-(*1R*, 5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methyl-benzyl)amide,

(*rac.*)-(*1R*, 5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3λ^6-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide,

(*rac.*)-(*1R*, 3R*, 5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3λ^4-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(3-methoxy-2-methylbenzyl)amide,

(*rac.*)-(*1R*, 3R*, 5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxo-3λ⁴-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2-methoxy-3-methylpyridin-4-ylmethyl)amide,

(*rac.*)-(*1R*, 5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxy-propoxy)-3-methylpyridin-4-ylmethyl]amide, and

(*rac.*)-(*1R*, 5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3λ⁶-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide.

7. (Currently amended) ~~Pharmaceutical compositions containing~~ A pharmaceutical composition comprising at least one compound of ~~any ones of claims 1 to 6~~ claim 1 and ~~usual carrier materials and adjuvants for the treatment or prophylaxis of disorders which are associated with a dysregulation of the renin-angiotensin system (RAS), comprising cardiovascular and renal diseases hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases known to be related to the RAS~~ a carrier and/or an adjuvant.

8. (Currently amended) A method for the treatment or prophylaxis of ~~diseases which are related to the RAS~~ RAS-associated diseases comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications,

complications after vascular or cardiac surgery, restenosis, or complications of treatment with immunosuppressive agents after organ transplantation, ~~and other diseases which are related to the RAS,~~ which method comprises administering a compound according to ~~any one of claims 1 to 6~~ claim 1 to a human being or animal.

9. (Cancelled).

10. (Cancelled).